FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

研究用のみ。 完全な免責事項 →

ペプチドライブラリー

PE-22-28

Proenkephalin Fragment

Fat Loss & Body Composition

PE-22-28 is a synthetic heptapeptide derived from the active region of Spadin, a naturally occurring peptide that functions as a specific antagonist of the TREK-1 potassium channel (KCNK2), a validated target for antidepressant therapy. By blocking TREK-1 channels, it produces rapid-onset antidepressant effects similar to those observed with SSRIs but within days rather than weeks, while also promoting hippocampal neurogenesis. Its primary research applications focus on treatment-resistant depression, cognitive enhancement, and neuroplasticity modulation.

作用機序

Fragment of proenkephalin that modulates opioid receptor signaling in adipose tissue. Promotes brown adipose tissue thermogenesis and white adipose tissue browning. Enhances uncoupling protein 1 (UCP1) expression, increasing non-shivering thermogenesis and energy expenditure.

研究プロトコル

研究目的のみで使用。医療アドバイスではありません。

Research protocols use 500mcg-1mg subcutaneously daily. Limited human data. Animal studies used varying doses. Often discussed alongside other fat-loss peptides. Cycles of 4-8 weeks.

研究ノート

Clinical Research Status

PE-22-28 is in preclinical research stages, building on the published work demonstrating Spadin and its analogs as a novel class of antidepressants acting through TREK-1 channel blockade. The parent compound Spadin was characterized by researchers at CNRS and University of Nice, with PE-22-28 representing an optimized shorter fragment with improved stability and blood-brain barrier penetration. No human clinical trials have been initiated specifically for PE-22-28, though the TREK-1 target has been validated in multiple preclinical depression models.

Key Published Findings

Research demonstrates that PE-22-28 produces antidepressant-like effects in mouse models (forced swim test, tail suspension test) within 4 days of administration, compared to 2-3 weeks required for SSRI onset of action. TREK-1 knockout mice display a depression-resistant phenotype identical to the effects produced by pharmacological blockade with PE-22-28 and related analogs. The compound has been shown to stimulate hippocampal neurogenesis and increase BDNF expression, providing a mechanistic basis for both its antidepressant and potential cognitive-enhancing effects through neuroplasticity promotion.

Safety Profile

Preclinical studies suggest good tolerability with no observed toxicity at effective antidepressant doses in animal models. TREK-1 channels are expressed in multiple tissues beyond the brain (heart, smooth muscle, adrenal gland), raising theoretical concerns about peripheral effects that have not been fully characterized. As a research compound without human trial data, the safety profile in humans including appropriate dosing, potential for dependence, and long-term effects on channel regulation remains undetermined.

Drug Interactions & Contraindications

Theoretical interactions exist with existing antidepressant medications (SSRIs, SNRIs, MAOIs) as combining multiple mechanisms affecting serotonergic and neuroplasticity pathways could produce unpredictable effects. TREK-1 channels play roles in neuroprotection during ischemia, so concurrent use with compounds affecting cerebrovascular function warrants caution. Individuals with cardiac arrhythmias should exercise caution given the expression of TREK-1 channels in cardiac tissue, though the degree to which PE-22-28 affects peripheral channels at therapeutic brain concentrations is unknown.

Comparison to Related Compounds

Spadin (the parent peptide) is a 17-amino-acid peptide with the same mechanism but poorer stability and shorter half-life compared to the optimized PE-22-28 fragment. Unlike SSRIs which require 2-4 weeks for therapeutic onset and carry sexual dysfunction and emotional blunting side effects, TREK-1 antagonism offers rapid-onset antidepressant action through a fundamentally different mechanism. Ketamine and its analogs also provide rapid antidepressant effects but through NMDA receptor antagonism with dissociative side effects and abuse potential that are not associated with TREK-1 blockade.

Community Observations

Users exploring PE-22-28 typically report noticeable mood improvements and cognitive clarity within 3-7 days of intranasal or subcutaneous administration at doses extrapolated from preclinical research (typically in the low microgram range). Reports suggest it produces a calm, clear-headed improvement in mood without the emotional numbing or sexual side effects commonly associated with SSRI medications. The research community notes that PE-22-28 represents one of the few peptide-based approaches to depression with a clearly validated molecular target, though sourcing verified high-purity material remains challenging due to its relative obscurity compared to mainstream research peptides.

半減期

~1-2 hours

再構成

Bacteriostatic water (BAC)

保存

乾燥粉末

Refrigerate 2-8C up to 12 months.

再溶解

Refrigerate 2-8C. Use within 14 days.

米国法的状況

Research chemical (not FDA-approved)

また知られる名前

Proenkephalin Fragment

よくある質問

PE-22-28とは何ですか?

PE-22-28 is a synthetic heptapeptide derived from the active region of Spadin, a naturally occurring peptide that functions as a specific antagonist of the TREK-1 potassium channel (KCNK2), a validated target for antidepressant therapy. By blocking TREK-1 channels, it produces rapid-onset antidepressant effects similar to those observed with SSRIs but within days rather than weeks, while also promoting hippocampal neurogenesis. Its primary research applications focus on treatment-resistant depression, cognitive enhancement, and neuroplasticity modulation.

PE-22-28はどのように作用しますか?

Fragment of proenkephalin that modulates opioid receptor signaling in adipose tissue. Promotes brown adipose tissue thermogenesis and white adipose tissue browning. Enhances uncoupling protein 1 (UCP1) expression, increasing non-shivering thermogenesis and energy expenditure.

PE-22-28の米国での規制状況は?

Research chemical (not FDA-approved)

PE-22-28の半減期は?

~1-2 hours

PE-22-28の別名は?

Proenkephalin Fragment

ペプチドコンタクトは、研究目的のみのための要約情報を提供しています。私たちはベンダーの文書をホスト、配布、または推奨していません。すべての分析証明書、GMP認定証明書、およびベンダーコミュニケーションは、購入者によって直接要求され、確認される必要があります。このプラットフォーム上の何らかの情報は法的、医学的、または専門的なアドバイスを構成していません。ユーザーは、適切な法律、州法、および連邦法に準拠するためにベンダー資格を検証し、購入前に遵守することに全責任を持つ必要があります。このプラットフォームを使用することで、完全な個人的責任を承認することになります。

完全な免責事項を読む